SSRI use not associated with cataract risk
Use of selective serotonin reuptake inhibitors (SSRIs) does not appear to increase the risk of cataract, reports a recent study.
Researchers identified a total of 206,931 cataract cases matched with the same number of controls. There was no association between current long-term use of SSRI (≥20 prescriptions) and an increased cataract risk (adjusted odds ratio [aOR], 0.99; 95 percent CI, 0.94 to 1.03). On the other hand, a slightly increased risk of cataract was seen for long-term SSRI users compared with nonusers in a subgroup of patients aged 40 to 64 years.
“The slightly increased OR for individuals younger than 65 years of age in association with long-term SSRI use needs to be investigated in further studies,” researchers said.
In this case-control study, the authors derived the participants from the UK-based Clinical Practice Research Datalink (CPRD). Included were patients with first-time cataract aged ≥40 years between 1995 and 2015 and an equal number of cataract-free controls matched on age, sex, general practice, date of cataract recording (ie, index date) and years of history in the CPRD before the index date.
Conditional logistic regression analyses were conducted, adjusting for body mass index, smoking, hypertension, diabetes and systemic steroid use. The number of SSRI prescriptions and prescriptions for other antidepressant drugs were the exposure of interest. Mutually exclusive use of single SSRI substances was explored.
The index data was shifted backwards by 2 years in sensitivity analyses. Also, analyses were restricted to cases and controls without a prior glaucoma diagnosis.